Trovagene, Inc. (TROV) 10-K Annual Report March 2019

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2018	Feb. 15, 2019	Jun. 30, 2018
Document and Entity Information
Entity Registrant Name	Trovagene, Inc.
Entity Central Index Key	0001213037
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding (shares)		4,021,507
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 13,220,162

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1213037/000162828019002546/trov-123118x10k.htm

View differences made from one year to another to evaluate Trovagene, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Trovagene, Inc..

Continue

Assess how Trovagene, Inc.'s management team is paid from their Annual Proxy

Trovagene, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Revenue

Financial

M & A

Other

Filter Subcategory:

All

Product

Expense

Debt

Geography

Other

Inside Trovagene, Inc.'s 10-K Annual Report:

Revenue - Product Highlight
Revenue is recognized when the criteria described above have been met as well as the following: Up-front nonrefundable license fees pursuant to agreements under which we have no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is probable.

Revenue - Product Highlight
Total revenues consisted of the following: The $34,991 decrease in royalty income in the year ended December 31, 2018 is mainly due to the termination of certain royalty agreements.
Financial - Shares Highlight
Basic and diluted net loss per share for the year ended December 31, 2018 were impacted by the increase in both basic and diluted weighted-average shares outstanding resulting from the sale and issuance of approximately 1.5 million shares of common stock through a public offering, the issuance of approximately 1.5 million shares of common stock upon conversion of Series B Convertible Preferred Stock, and issuance of approximately 0.1 million shares of common stock in connection with the exercise of warrants and vesting of restricted stock units.
Revenue - Product Highlight
This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied.
Financial - Expense Highlight
Stock-based compensation expense related to stock options for employees and directors is recognized in the consolidated statement of operations based on estimated amounts, including the grant date fair value and the expected service period.
Other - Other
We could utilize our available...Read more
Financial - Shares
In a concurrent private placement,...Read more
Financial - Shares
On December 19, 2017 we...Read more
Financial - Expense
Research and Development Research and...Read more
Financial - Expense
The risk of completion of...Read more
Financial - Expense
As the related goods are...Read more
Other - Other
The increase in working capital...Read more
Financial - Expense
Therefore, our personnel related costs...Read more
Financial - Shares
On March 15, 2017, we...Read more
Financial - Expense
The decrease of interest expense...Read more
Financial - Expense
Research and development expenses related...Read more
Financial - Expense
Research and development expenses consisted...Read more
Financial - Expense
Compensation expense for RSU and...Read more
Other - Other
If we do not regain...Read more
Other - Other
Unique to our clinical development...Read more
Other - Other
This Registration Statement was declared...Read more
Revenue - Product
We are evaluating all options...Read more
Other - Other
A performance obligation is considered...Read more
Financial - Debt
The preferred stock, debt securities,...Read more
Other - Other
We consider a performance obligation...Read more
Financial - Expense
Selling, general and administrative expenses...Read more
Financial - Shares
Each share of common stock...Read more
Other - Other
In addition, we have based...Read more
Other - Other
A delisting of our common...Read more
Financial - Expense
Restructuring Restructuring costs are included...Read more
Revenue - Product
Gross proceeds of $2.4 million...Read more
Financial - Shares
Gross proceeds of approximately $110,000...Read more
Other - Other
The net proceeds to us...Read more
Other - Other
The net proceeds to us...Read more
Other - Other
The net proceeds to us...Read more
M & A - Other
NASDAQ Notice On September 5,...Read more
Other - Other
Changes in fair value of...Read more
Other - Other
FASB ASC Topic 730, Research...Read more
Revenue - Product
For sales-based royalties, we recognize...Read more
Financial - Expense
More detailed discussions of our...Read more
Revenue - Geography
In in-vitro and in-vivo pre-clinical...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Trovagene, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Ticker: TROV
CIK: 1213037
Form Type: 10-K Annual Report
Accession Number: 0001628280-19-002546
Submitted to the SEC: Wed Mar 06 2019 11:05:28 AM EST
Accepted by the SEC: Wed Mar 06 2019
Period: Monday, December 31, 2018
Industry: Biological Products No Disgnostic Substances